J&J's Janssen Biotech gets option to Dendright's RA vaccine
Executive Summary
Dendright Pty. Ltd. (a wholly owned division of UniQuest Pty. Ltd., the University of Queensland’s commercialization arm) has granted Johnson & Johnson’s Janssen Biotech Inc. an option for an exclusive global license to develop and market its rheumatoid arthritis (RA) vaccine.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice